encorafenib
Showing 1 - 25 of 39
Metastatic Colorectal Cancer Trial in Houston (Cetuximab, Ulixertinib, Encorafenib)
Not yet recruiting
- Metastatic Colorectal Cancer
- Cetuximab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2023
Solid Tumor Trial in Toronto (Binimetinib, Encorafenib)
Recruiting
- Solid Tumor
- Binimetinib
- Encorafenib
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Sep 23, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8 Trial in
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +2 more
- Binimetinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,
Not yet recruiting
- Metastatic Colorectal Adenocarcinoma
- +2 more
- BET Bromodomain Inhibitor ZEN-3694
- +6 more
- (no location specified)
Oct 25, 2023
Melanoma Trial in Worldwide (encorafenib, binimetinib, pembrolizumab)
Recruiting
- Melanoma
- encorafenib
- +4 more
-
Siena, Toscana, Italy
- +11 more
Jun 23, 2023
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,
Not yet recruiting
- Colon Adenocarcinoma
- +4 more
- Encorafenib
- +5 more
- (no location specified)
Jan 24, 2023
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,
Recruiting
- BRAF NP_004324.2:p.V600M
- +6 more
- Binimetinib
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Aug 17, 2022
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)
Completed
- BRAF V600E Unresectable or Metastatic Melanoma
- +2 more
- Encorafenib
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 9, 2022
Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,
Active, not recruiting
- Metastatic Malignant Neoplasm in the Brain
- +7 more
- Binimetinib
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jun 15, 2022
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Terminated
- Metastatic Colon Adenocarcinoma
- +27 more
- Binimetinib
- +3 more
-
San Francisco, California
- +1 more
Jan 5, 2023
Melanoma Trial in Pittsburgh (encorafenib, nivolumab, ipilimumab)
Recruiting
- Melanoma
- encorafenib
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 24, 2022
Cancer Trial in Melbourne (Trametinib, Cobimetinib, Binimetinib)
Recruiting
- Cancer
- Trametinib
- +14 more
-
Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
Nov 4, 2022
Metastatic Colorectal Cancer Trial in Oslo (Alectinib, Cetuximab, Crizotinib)
Recruiting
- Metastatic Colorectal Cancer
- Alectinib
- +16 more
-
Oslo, NorwayOslo University Hospital
Feb 10, 2023
Malignant Melanoma Trial in Herlev, Aarhus, Odense (Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab
Recruiting
- Malignant Melanoma
- Pembrolizumab Injection [Keytruda]
- +6 more
-
Herlev, Hovedstaden, Denmark
- +2 more
Sep 16, 2022
Metastatic Melanoma, Brain Metastases Trial in Spain (encorafenib, binimetinib, Whole brain radiation therapy)
Recruiting
- Metastatic Melanoma
- Brain Metastases
- encorafenib
- +3 more
-
Palma De Mallorca, Baleares, Spain
- +20 more
Feb 16, 2022
BRAF V600E, Metastatic Colorectal Cancer Trial in China (Encorafenib, Cetuximab, FOLFIRI)
Recruiting
- BRAF V600E
- Metastatic Colorectal Cancer
- Encorafenib
- +2 more
-
Beijing, Beijing, China
- +33 more
Dec 20, 2022
Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)
Not yet recruiting
- Malignant Melanoma
- +4 more
- Pembrolizumab
- +2 more
- (no location specified)
Mar 31, 2022
Melanoma, Metastasis Trial in Melbourne (Binimetinib, Encorafenib, Palbociclib)
Recruiting
- Melanoma
- Metastasis
- Binimetinib
- +2 more
-
Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
Jan 19, 2021
BRAF V600E-mutant Metastatic Colorectal Cancer Trial in Worldwide (encorafenib, Binimetinib, Cetuximab)
Active, not recruiting
- BRAF V600E-mutant Metastatic Colorectal Cancer
- encorafenib
- +2 more
-
New York, New York
- +44 more
Aug 8, 2022
Targeted Therapies in BRAF Positive Metastatic Melanoma in US
Active, not recruiting
- Melanoma
- Encorafenib
- +5 more
-
New York, New YorkPfizer Investigational Site
Feb 18, 2022